Anti-SARS-CoV-2 Monoclonal Antibodies C135-LS/C144-LS

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A combination of two human immunoglobulin G1 (IgG1) monoclonal antibodies C135-LS and C144-LS directed against the spike protein (SP) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that are isolated from convalescent patients with SARS-CoV-2 infection and engineered with a mutation to prolong their half-lives, that can potentially be used for immunization against COVID-19. Upon administration, anti-SARS-CoV-2 monoclonal antibodies C135-LS/C144-LS specifically target and bind to two distinct epitopes on the receptor-binding domain (RBD) of SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. Binding to two distinct regions of the RBD of SP may decrease the potential for virus escape mutants that occur upon treatment with a single SARS-CoV-2 antibody, and may provide enhanced protection against loss of efficacy.

**Synonyms:** - Anti-SARS-CoV-2 Monoclonal Antibodies BMS-986413 + BMS-986414 - Anti-SARS-CoV-2 Monoclonal Antibodies BMS-986413/BMS-986414 - Anti-SARS-CoV-2 Monoclonal Antibodies C135-LS + C144-LS - BMS-986413 + BMS-986414 - BMS-986413/BMS-986414 - C135-LS + C144-LS - C135-LS Plus C144-LS - C135-LS and C144-LS - C135-LS/C144-LS